Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 06835375

Drug Profile

PF 06835375

Alternative Names: PF-06835375

Latest Information Update: 10 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action CXCR5 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura
  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 03 Jun 2023 PF 06835375 is still in phase I trials for Systemic-lupus-erythematosus and Rheumatoid-arthritis in USA (NCT03334851)
  • 03 Jun 2023 Safety and pharmacokinetics data from a phase I trial in Systemic lupus erythematosus and Rheumatoid arthritis were presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023) .
  • 18 Apr 2023 Pfizer re-initiates a phase II trial in Idiopathic thrombocytopenic purpura (In adults, In the elderly) in Canada, Czech Republic, Czech Republic, Australia, Poland, Hungary and USA (SC) (NCT05070845)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top